Rosseti North-West (MOEX:MRKZ)
Russia · Delayed Price · Currency is RUB 0.0275
+0.0002 (0.73%)
At close: Jul 8, 2022
Revance Therapeutics Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 67,746 | 62,720 | 53,710 | 48,331 | 50,352 | 48,253 | Upgrade | |
Revenue Growth (YoY) | 23.33% | 16.78% | 11.13% | -4.01% | 4.35% | -1.80% | Upgrade |
Operations & Maintenance | 1,080 | 1,055 | 877.7 | 646.51 | 606.19 | - | Upgrade |
Selling, General & Admin | 21.32 | 27 | 16.09 | 21.12 | 72.96 | 55.92 | Upgrade |
Provision for Bad Debts | -73.98 | 9.25 | -245.71 | 385.08 | 199.52 | 915.6 | Upgrade |
Other Operating Expenses | 63,191 | 59,254 | 50,447 | 43,926 | 46,639 | 46,526 | Upgrade |
Total Operating Expenses | 64,218 | 60,345 | 51,095 | 44,979 | 47,518 | 47,497 | Upgrade |
Operating Income | 3,528 | 2,375 | 2,615 | 3,352 | 2,834 | 755.63 | Upgrade |
Interest Expense | -2,920 | -2,798 | -1,855 | -2,094 | -1,039 | -1,044 | Upgrade |
Interest Income | 1,361 | 1,041 | 306.56 | 195.4 | 44.06 | 38.41 | Upgrade |
Net Interest Expense | -1,559 | -1,757 | -1,548 | -1,898 | -995.42 | -1,005 | Upgrade |
Other Non-Operating Income (Expenses) | -220.92 | -220.99 | 13.02 | 7.71 | 7.32 | 152.37 | Upgrade |
EBT Excluding Unusual Items | 1,748 | 397.12 | 1,080 | 1,461 | 1,845 | -97.4 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 54.81 | -280.57 | 22.37 | -72.13 | Upgrade |
Gain (Loss) on Sale of Assets | 517.1 | 516.72 | 622.4 | 294.09 | 8.97 | -3.09 | Upgrade |
Asset Writedown | -43.52 | -43.62 | -2,990 | -2,244 | -2,950 | -1,132 | Upgrade |
Insurance Settlements | 106.29 | 198.42 | 93.67 | 63.29 | 52.79 | 32.98 | Upgrade |
Pretax Income | 2,328 | 1,069 | -1,140 | -706.38 | -1,020 | -1,272 | Upgrade |
Income Tax Expense | 987.27 | 601.34 | -115.81 | -54.28 | -137.48 | -131.52 | Upgrade |
Earnings From Continuing Ops. | 1,340 | 467.3 | -1,024 | -652.1 | -882.8 | -1,141 | Upgrade |
Earnings From Discontinued Ops. | - | 1,320 | 472.93 | 393.16 | - | - | Upgrade |
Net Income to Company | 1,340 | 1,787 | -550.97 | -258.95 | -882.8 | -1,141 | Upgrade |
Minority Interest in Earnings | - | - | - | -0.25 | 0.01 | 0.02 | Upgrade |
Net Income | 1,340 | 1,787 | -550.97 | -259.19 | -882.79 | -1,141 | Upgrade |
Net Income to Common | 1,340 | 1,787 | -550.97 | -259.19 | -882.79 | -1,141 | Upgrade |
Net Income Growth | 143.19% | - | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 95,786 | 95,786 | 95,786 | 95,786 | 95,786 | 95,786 | Upgrade |
Shares Outstanding (Diluted) | 95,786 | 95,786 | 95,786 | 95,786 | 95,786 | 95,786 | Upgrade |
EPS (Basic) | 0.01 | 0.02 | -0.01 | -0.00 | -0.01 | -0.01 | Upgrade |
EPS (Diluted) | 0.01 | 0.02 | -0.01 | -0.00 | -0.01 | -0.01 | Upgrade |
EPS Growth | 143.21% | - | - | - | - | - | Upgrade |
Free Cash Flow | 7,140 | 7,377 | 3,385 | 587.02 | -346.36 | 106.34 | Upgrade |
Free Cash Flow Per Share | 0.07 | 0.08 | 0.04 | 0.01 | -0.00 | 0.00 | Upgrade |
Profit Margin | 1.98% | 2.85% | -1.03% | -0.54% | -1.75% | -2.36% | Upgrade |
Free Cash Flow Margin | 10.54% | 11.76% | 6.30% | 1.21% | -0.69% | 0.22% | Upgrade |
EBITDA | 8,183 | 6,864 | 7,139 | 7,862 | 7,089 | 5,160 | Upgrade |
EBITDA Margin | 12.08% | 10.94% | 13.29% | 16.27% | 14.08% | 10.70% | Upgrade |
D&A For EBITDA | 4,655 | 4,490 | 4,524 | 4,511 | 4,256 | 4,405 | Upgrade |
EBIT | 3,528 | 2,375 | 2,615 | 3,352 | 2,834 | 755.63 | Upgrade |
EBIT Margin | 5.21% | 3.79% | 4.87% | 6.93% | 5.63% | 1.57% | Upgrade |
Effective Tax Rate | 42.42% | 56.27% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Utility template. Financial Sources.